Skip to content
Grochi · Neutral pet information from South Korea · English edition한국어
Grochi.English edition
Health care

What have regulators said about isoxazoline flea and tick products?

Translated from the Korean edition · Editorial draft, not professionally reviewed. This page is an English translation of the Korean edition as checked on 2026-11-22. If the two differ, the Korean edition is the reference. 한국어판 (Korean edition)

What have regulators said about isoxazoline flea and tick products?
Short answer

In September 2018 the US FDA said that muscle tremors, ataxia and seizures had been reported with isoxazoline products and asked that this be added to labeling. It did not ban the products; it asked that the animal's history be reviewed with a veterinarian.

Key takeaways

  • On September 20, 2018, the US FDA Center for Veterinary Medicine said that neurologic adverse events such as muscle tremors, ataxia and seizures had been reported in some dogs and cats given isoxazoline flea and tick products by mouth or on the skin.
  • The FDA maintained that these products continue to be safe and effective for the majority of animals, and said it asked manufacturers to add information on neurologic adverse events to labeling. It did not ban the products.
  • The FDA wrote that seizures may occur in animals with no earlier history of seizures, and advised reviewing the animal's medical history with a veterinarian before choosing a product.
  • In 2017 the European Medicines Agency (EMA) reviewed one fluralaner product and concluded its safety remained acceptable, while adding convulsions to the package leaflet as a very rare adverse reaction and advising caution in dogs with epilepsy.
  • In the sources this article read, no announcement from the Animal and Plant Quarantine Agency (APQA) or other Korean agencies aimed specifically at the isoxazoline class was found. For Korean products, follow the package insert and your veterinarian's explanation.

What have regulators said about the isoxazoline class? The short answer first

In short, what the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) said was not “stop using these products.” It was “neurologic adverse events have been reported, so put this in the labeling, and review the animal's history with a veterinarian before use.” The FDA Center for Veterinary Medicine (CVM) issued a safety communication on September 20, 2018, stating that muscle tremors, ataxia (an unsteady, uncoordinated gait) and seizures had been reported in some animals given isoxazoline flea and tick products. At the same time, it maintained its view that these products continue to be safe and effective for the majority of animals.

What the isoxazoline class is, and how its mode of action differs from other external parasite ingredients, was covered in the already published article “How do flea and tick ingredients such as fipronil, imidacloprid and the isoxazoline class differ? (외부 구충제 성분(피프로닐·이미다클로프리드·이속사졸린 계열 등)은 어떻게 다른가요?)”. This article covers one thing only: which documents regulators actually issued, when, and what those documents say and do not say.

This article does not evaluate or compare products. It does not say any ingredient is safer or less safe than another, and it relays only what the agencies wrote, mostly by ingredient name. It does not cover how to administer these products or doses. Actual use should follow the veterinarian's judgment and the product instructions.

When reading regulatory documents, it helps to separate two things. One is the fact that “adverse events were reported.” The other is the judgment that “the product was confirmed as the cause.” A communication is a document that relays adverse event reports; it does not sort out which product caused what in an individual animal. Below, this article follows only what the original documents wrote.

What exactly does the September 2018 FDA communication say?

The FDA CVM “Animal Drug Safety Communication” was issued on September 20, 2018, and informs pet owners and veterinarians of the potential for neurologic adverse events associated with certain flea and tick products. The FDA wrote that muscle tremors, ataxia and seizures had been reported in some animals given these products, and explained that these events were not limited to one product but were seen consistently across the isoxazoline class.

The products named in the communication were fluralaner tablets (for dogs) and topical solution (for cats and dogs), afoxolaner tablets (for dogs), sarolaner tablets (for dogs) and lotilaner tablets (for dogs); in the April 2019 update, a cat topical solution combining selamectin and sarolaner was added. By ingredient, that is fluralaner, afoxolaner, sarolaner and lotilaner. The Merck Veterinary Manual entry on isoxazoline toxicosis also lists the same four ingredients, noting that the FDA said in September 2018 that these ingredients can have neurologic effects in some dogs.

The FDA's actions can be summarized in two points. First, it asked manufacturers to add information highlighting neurologic adverse events to labeling. As an update, the communication records that the selamectin and sarolaner combination was approved with this new label information, and that for one product already on the market (afoxolaner) the manufacturer added a class statement to the label. Second, it shared the information so that owners and veterinarians could decide animal by animal.

The FDA says these products continue to be safe and effective for the majority of animals. It also advises veterinarians to review each animal's medical history with the owner and decide whether an isoxazoline product is appropriate. Adverse events can be reported to the manufacturer or to the FDA, and the communication states that drug sponsors must report serious, unexpected adverse events to the FDA within 15 days.

It is also worth being clear about what the communication did not say. It did not ban the sale or use of these products, did not revoke approvals, and did not rank products by risk. A sentence that rules out use in animals with a seizure history was not found in what this article read.

What changed in the later updates and the fact sheet?

The communication did not end with one release. It was updated twice afterward, and a separate fact sheet on the same topic is maintained. The dates and contents, as the originals state them, are summarized in the table below. The table lists what changed on each date; it is not an evaluation of products.

In terms of what the updates contain, the communication's updates adjusted the list of covered products and approval-holder information. The April 2019 update added one newly approved isoxazoline product to the list, and the August 2019 update reflected a change of approval holder for one product. The fact sheet has continued to reflect newly approved products and, as of August 8, 2023, lists 11 products. Some of them are combination products that mix an isoxazoline with other ingredients such as moxidectin, pyrantel, praziquantel and eprinomectin. In the documents this article read, it was not distinguished whether the adverse event information for a combination product is due to the isoxazoline ingredient or to another ingredient.

In the fact sheet, the FDA explains that these products have been used safely in the majority of dogs and cats, and that most dogs and cats did not have neurologic adverse reactions. It then writes that seizures may occur in animals without a prior history of seizures, and advises owners to review the animal's medical history with a veterinarian before using the product. If an adverse event occurs, it says to consult the veterinarian first and to report to the manufacturer or the FDA.

The FDA wrote in the fact sheet that it continues to monitor adverse event reports for these products. There may be actions after the time this article read these documents (2026-11-22), or actions not reflected in the fact sheet, so it is best to check the latest content directly in the FDA originals.

Dated contents of the FDA safety communication and fact sheet (as the originals state, not a product evaluation)
DateDocumentWhat the original says
2018-09-20Safety communication (first issued)Muscle tremors, ataxia and seizures reported with isoxazoline products. Manufacturers asked to add information on neurologic adverse events to labeling. Described as continuing to be safe and effective for the majority of animals
2019-04-22Safety communication updateNewly approved selamectin and sarolaner combination cat topical solution added to the list
2019-08-08Safety communication updateReflected a change of approval holder for one product (afoxolaner). Last update date of this communication
2023-08-08Fact sheet for pet owners and veterinarians (date the current content is dated)Lists 11 isoxazoline products; explains neurologic adverse events and that seizures can occur in animals without a seizure history; advises history review and adverse event reporting

What did the European Medicines Agency (EMA) say?

The EMA material this article opened and read directly is one press release published on August 17, 2017. Its title is “Tick and flea control agent Bravecto continues to be acceptably safe to use” (the name as given in the authorization information), and it announces a conclusion reached by the Committee for Medicinal Products for Veterinary Use (CVMP) in July 2017. This article mentions the product not to evaluate or compare it but because it is the subject of the EMA document. Its ingredient is fluralaner, and the document states that the product was authorized in the EU on February 11, 2014.

As the reason for the review, the EMA explains that data on some serious adverse events were unclear, so the marketing authorization holder was asked to investigate reports of neurological, skin, hypersensitivity and immune-mediated reactions and liver disorders. As a result, the committee concluded that the product continues to have an acceptable safety profile.

Two points appear regarding product information. One is a requirement to add convulsions to the package leaflet as an adverse reaction; the document describes this as “reported very rarely,” that is, fewer than 1 animal in 10,000 treated. The company had to implement this within 6 months of the committee's conclusion. The other is advice to veterinarians and owners to use the product with caution in dogs with epilepsy.

The document also contains reporting figures. Between February 2014 and December 2016, about 41,600,000 doses were distributed worldwide, of which about 18,000,000 were in the EU. As of August 15, 2017, suspected adverse reactions had been reported for 5,326 dogs worldwide (2,144 in the EU), and deaths had been reported for 1,265 dogs worldwide (342 in the EU). However, the EMA stated clearly that each report concerns dogs with different health conditions, often receiving multiple medicines, so these figures may or may not be related to use of the product. These figures should not be read directly as a probability of risk.

The limits of this material should also be stated. It is a 2017 press release, not the body of the EPAR (European Public Assessment Report) or the current product information, and EMA documents on other isoxazoline ingredients and later updates were not opened and read. The current content of the adverse reaction and precaution sections of the EPAR was not checked, so it is not generalized here.

What does the Merck Veterinary Manual entry on isoxazoline toxicosis explain?

The Merck Veterinary Manual entry “Isoxazoline Toxicosis in Animals” introduces the class as external parasite ingredients used against fleas and ticks on dogs and cats. The explanation of the mode of action and its selectivity for the parasite is the same as what was covered in the ingredients article mentioned earlier, so it is not repeated here. However, an explanation of high selectivity does not mean that no animal has adverse reactions.

The entry summarizes the FDA's September 2018 communication, relaying that afoxolaner, fluralaner, sarolaner and lotilaner can have neurologic effects in some dogs, with muscle tremors, ataxia and seizures reported as signs.

The ingredient-by-ingredient explanation includes pharmacokinetic information. For example, it says afoxolaner is largely bound to plasma proteins in dogs and is excreted mainly through bile, and that sarolaner has a long half-life of about 11 to 12 days. These numbers are reference information for understanding the nature of the products and are not usage guidance.

On treatment, the limits are clear. The entry explains that there is no specific antidote for afoxolaner poisoning and that management centers on preventing further exposure and supportive care. In other words, when an adverse reaction occurs, there is no treatment that can be given at home; assessment and supportive care by a veterinarian are central.

What have Korean regulators said about the isoxazoline class?

Among the materials this article opened and read, there was no announcement from a Korean agency dealing specifically with neurologic adverse events of the isoxazoline class. This article therefore does not state that a Korean agency issued guidance on the isoxazoline class, nor that it did not; it says only that none was found. Not finding something is not proof that it does not exist.

What was confirmed in Korean rules is general provisions. Article 14(1)(4) of the Regulations on Handling of Veterinary Medicinal Products (동물용 의약품등 취급규칙) provides that when a manufacturer obtains new data related to the safety and efficacy of an approved or notified item, or learns of information including adverse reaction cases, it is to take necessary safety measures. Article 7-2 of the same Regulations provides that, when applying for re-examination of new drugs and the like, the applicant submits safety reports in Korea and abroad on adverse reactions and the like obtained during the re-examination period, and that necessary measures such as a change of approved matters are taken according to the re-examination result. Article 37-3 of the Pharmaceutical Affairs Act (약사법) provides that a holder of an item approval carries out post-marketing safety management work such as adverse reaction reporting, and that a holder of approval for a medicine intended only for animals may carry out this work with a veterinarian.

These provisions are general rules that apply to veterinary medicinal products as a whole; they do not designate the isoxazoline class. This article also did not check which product's package insert, if any, these provisions actually changed. Which isoxazoline products are approved in Korea, for which animals and in what form, and how neurologic adverse reactions are written in their package inserts, were not confirmed in this article. Because the US and European documents cannot be assumed to match the labeling of Korean approved products, the precautions of a Korean approved product should be checked directly in its package insert and in the approval information of the Animal and Plant Quarantine Agency (APQA).

The reporting route in Korea for adverse reactions after using a veterinary medicinal product was not checked in this article and is covered in a separate article.

What should owners check, and what are common misconceptions?

Based on the documents this article introduced, here is a checklist that may help when talking with a veterinarian before choosing a product. This list is preparation for a consultation, not an instruction to choose a medicine.

  • Whether the ingredient name of the product in use (or about to be used) belongs to the isoxazoline class (fluralaner, afoxolaner, sarolaner, lotilaner and others)
  • If it is a combination product, which ingredients it contains together
  • Whether the animal has ever had seizures, tremors or stumbling, or has been diagnosed with epilepsy
  • Whether other medicines or external parasite products have been used recently
  • The target animal (dog or cat) and the precautions stated in the product's package insert
  • Whom to contact if symptoms appear after use (veterinarian, manufacturer)

Here are some common misconceptions. First, the statement that “regulators banned its use” does not match the documents this article read. The FDA maintained its position that the products are safe and effective for the majority of animals while asking for stronger labeling and history review, and the EMA concluded safety was acceptable while having convulsions added as a very rare adverse reaction. Second, the idea that “only animals with a seizure history are at issue” also differs from the FDA's explanation. The FDA wrote that seizures may occur in animals without a prior seizure history. Third, the idea that “all isoxazolines are the same” or that “only one ingredient is the problem” has no basis. The FDA explains that this phenomenon was seen across the class, but the documents contain no ranking among ingredients. Fourth, the idea that “the number of adverse event reports is the probability of risk” is also risky. The EMA document itself stated that these figures may or may not be related to the product.

Finally, none of the sources in this article recommends substituting medicines for other animals or for people, or splitting doses on one's own. The basic rule is to use a product approved for the target animal according to its instructions.

When to contact a veterinarian

If muscle tremors, stumbling (ataxia) or seizures are seen after using an isoxazoline product, contact an animal hospital immediately without delay. The FDA advises consulting the veterinarian first when an adverse event occurs, and a sudden symptom such as a seizure is not something to wait and watch. When you go to the hospital, it helps to bring the product packaging, the ingredient name, the time of use and any earlier neurologic symptoms.

Before using a product, talk with a veterinarian first, especially about an animal with a history of seizures or epilepsy. The EMA document advises caution in dogs with epilepsy, and the FDA recommends a history review. This article does not sort out which animals are at risk; that judgment belongs to the veterinarian who knows the medical record.

This article is general information compiled from regulators' public documents and is not a diagnosis or prescription. Whether a particular product suits your pet, or whether a product already in use may be continued, cannot be decided from this article. The details of how to check and report adverse reactions are covered in a separate article.

Frequently asked questions

Q Did the FDA ban isoxazoline flea and tick products?

No. In its September 20, 2018 safety communication, the FDA said muscle tremors, ataxia and seizures had been reported with this class and asked manufacturers to strengthen labeling, but stated that the products continue to be safe and effective for the majority of animals. The communication did not ban sale or use or revoke approvals.

Q If an animal has no seizure history, can I stop worrying about neurologic adverse events?

That cannot be said. The FDA fact sheet says most dogs and cats did not have these reactions, but also writes that seizures may occur in animals without a prior history of seizures. The FDA's advice is to review the animal's history with a veterinarian before using a product.

Q Did the list of ingredients in the FDA documents grow after the 2018 communication?

In its April 22, 2019 update the communication added a cat topical solution combining selamectin and sarolaner, and on August 8, 2019 it reflected only a change of approval holder for one product. The fact sheet lists 11 products as of August 8, 2023, and the combination products include ingredients such as esafoxolaner.

Q What guidance was issued in Europe?

In a press release published on August 17, 2017, the EMA concluded that one fluralaner product continues to have an acceptable safety profile, had convulsions added to the package leaflet as a very rare adverse reaction, and advised caution in dogs with epilepsy. This article did not read the body of the EPAR or EMA documents on other ingredients.

Q Did the Korean government also issue a warning about isoxazoline products?

In the range this article searched and read, no announcement from a Korean agency dealing only with the isoxazoline class was found. That means it was not found, not that it does not exist. The precautions of a Korean approved product should be checked in its package insert and with a veterinarian.

Q Does the Merck Veterinary Manual say there is a special antidote for isoxazoline poisoning?

The entry explains that there is no specific antidote for afoxolaner poisoning and that management consists of preventing further exposure and giving supportive care. This does not mean treating the animal on your own at home; if symptoms appear, contact a veterinarian.

Limits and scope of this guide

This article is an editorial draft and did not go through professional review by veterinarians or pharmacists. It was compiled from reading the FDA communication and fact sheet, the EMA's 2017 press release (not the body of the EPAR), a Merck Veterinary Manual entry and Korean statutory provisions. An announcement by the Animal and Plant Quarantine Agency (APQA) or other Korean agencies on the isoxazoline class was not found, and the package inserts of Korean approved products, the current adverse reaction and precaution sections of the EPAR, EMA documents on other ingredients and any actions after the communication were not checked. Overseas documents may differ from Korean approval and labeling. The product and directions suited to an individual animal should follow a veterinarian and the product instructions, and for an animal with a history of seizures or epilepsy, do not use this article as the basis for choosing a product.

Translated from the Korean edition · Editorial draft, not professionally reviewed. The Korean edition is an explainer newly written from public sources; it is not a full translation of those sources. Veterinary expert review has not been completed. For decisions about your pet's health, talk to a veterinarian who knows your pet.

Sources and check dates

  1. Animal Drug Safety Communication: FDA Alerts Pet Owners and Veterinarians About Potential for Neurologic Adverse Events Associated with Certain Flea and Tick Products ↗

    Used as the basis for the September 20, 2018 issuance, the April 22 and August 8, 2019 updates, the products named and the labeling request, and the adverse event reporting guidance.

  2. Fact Sheet for Pet Owners and Veterinarians about Potential Adverse Events Associated with Isoxazoline Flea and Tick Products ↗

    Used as the basis for the product list as of August 8, 2023, seizures possible in animals without a prior seizure history, and the history review and adverse event reporting guidance.

  3. Tick and flea control agent Bravecto continues to be acceptably safe to use ↗

    Used as the basis for the 2017 CVMP conclusion, convulsions added as a very rare adverse reaction, caution in dogs with epilepsy, and the reporting figures and the caution about interpreting them.

  4. Isoxazoline Toxicosis in Animals ↗

    Used as the basis for the summary of the FDA's September 2018 communication, the selectivity of the mode of action, and the explanation that there is no specific antidote and supportive care is central.

  5. Regulations on Handling of Veterinary Medicinal Products (동물용 의약품등 취급규칙) (Articles 7-2 and 14) ↗

    Used as the basis for the manufacturer's duty to take safety measures on adverse reaction information (Article 14) and the submission of safety reports on adverse reactions and the like at re-examination (Article 7-2).

  6. Pharmaceutical Affairs Act (약사법) (Article 37-3) ↗

    Used as the basis for post-marketing safety management and adverse reaction reporting by the holder of an item approval, and the proviso for veterinary medicinal products.

Korean edition checked · translated · each source may have a different check date. No paid partnerships.

This guide relies on 2 Korean laws or notices. Current effective dates and upcoming amendments are listed on Korean law check status. This is not legal advice.